{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:14:11Z","timestamp":1785726851298,"version":"3.56.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.drudis.2025.104344","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:02:29Z","timestamp":1743271349000},"page":"104344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["JAK inhibitors as a promising therapy for immune-mediated photodermatoses"],"prefix":"10.1016","volume":"30","author":[{"given":"Mohammad","family":"Malekan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Taghiloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armaghan","family":"Kazeminejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Montazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasem Rahmatpour","family":"Rokni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104344_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clindermatol.2013.05.027","article-title":"Photodermatoses, including phototoxic and photoallergic reactions (internal and external)","volume":"32","author":"Kutlubay","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-3-030-92616-8_14","article-title":"The immunogenetics of photodermatoses","volume":"1367","author":"Lee","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2025.104344_b0015","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/jdv.15115","article-title":"Photodermatoses in skin of colour","volume":"32","author":"Gutierrez","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.drudis.2025.104344_b0020","series-title":"StatPearls","article-title":"Photosensitivity","author":"Oakley","year":"2023"},{"key":"10.1016\/j.drudis.2025.104344_b0025","first-page":"135","article-title":"Photodermatoses: diagnosis and treatment","volume":"108","author":"Lehmann","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.drudis.2025.104344_b0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104344_b0035","series-title":"StatPearls","article-title":"Polymorphic light eruption","author":"Oakley","year":"2023"},{"key":"10.1016\/j.drudis.2025.104344_b0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.det.2014.03.012","article-title":"Polymorphous light eruption: clinic aspects and pathogenesis","volume":"32","author":"Gruber-Wackernagel","year":"2014","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.drudis.2025.104344_b0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/archderm.140.3.295","article-title":"Differential expression of cytokines in UV-B-exposed skin of patients with polymorphous light eruption: correlation with Langerhans cell migration and immunosuppression","volume":"140","author":"K\u00f6lgen","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.908047","article-title":"Accumulation of cytotoxic skin resident memory T cells and increased expression of IL-15 in lesional skin of polymorphic light eruption","volume":"9","author":"Patra","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2025.104344_b0055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fmed.2018.00252","article-title":"Polymorphic light eruption: what\u2019s new in pathogenesis and management","volume":"5","author":"Lembo","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2025.104344_b0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.det.2014.03.006","article-title":"Evaluation of patients with photodermatoses","volume":"32","author":"Choi","year":"2014","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.drudis.2025.104344_b0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00128071-200910030-00003","article-title":"Immunologically mediated photodermatoses: diagnosis and treatment","volume":"10","author":"Gambichler","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0070","series-title":"StatPearls","article-title":"Polymorphic light eruption","author":"Oakley","year":"2024"},{"key":"10.1016\/j.drudis.2025.104344_b0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1067\/moe.2002.123539","article-title":"Actinic prurigo cheilitis: clinicopathologic analysis and therapeutic results in 116 cases","volume":"94","author":"Vega-Memije","year":"2002","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.drudis.2025.104344_b0080","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1525-1470.2000.01818.x","article-title":"The conjunctivitis of solar (actinic) prurigo","volume":"17","author":"Maga\u00f1a","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0085","series-title":"StatPearls","article-title":"Actinic prurigo","author":"Pile","year":"2024"},{"key":"10.1016\/j.drudis.2025.104344_b0090","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s001050051178","article-title":"Actinic prurigo","volume":"51","author":"Lippert","year":"2000","journal-title":"Hautarzt"},{"key":"10.1016\/j.drudis.2025.104344_b0095","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1111\/ijd.13550","article-title":"Actinic prurigo as a hypersensitivity reaction type 4","volume":"56","author":"Vega Memije","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/abd1806-4841.20163941","article-title":"Correlation of serum IgE levels and clinical manifestations in patients with actinic prurigo","volume":"91","author":"Cuevas-Gonzalez","year":"2016","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1529-8019.2003.01606.x","article-title":"Diagnosis and treatment of actinic prurigo","volume":"16","author":"Hojyo-Tomoka","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.drudis.2025.104344_b0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2310\/6620.2011.10105","article-title":"Chronic actinic dermatitis: an analysis at a single institution over 25 years","volume":"22","author":"Que","year":"2011","journal-title":"Dermatitis"},{"key":"10.1016\/j.drudis.2025.104344_b0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/phpp.12402","article-title":"Increased incidence of chronic actinic dermatitis in relation to climate changes and air pollution during the past 15 years in Korea","volume":"34","author":"Kim","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.drudis.2025.104344_b0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.det.2014.03.007","article-title":"Chronic actinic dermatitis","volume":"32","author":"Paek","year":"2014","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.drudis.2025.104344_b0125","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jaci.2022.02.013","article-title":"Recognizing photoallergy, phototoxicity, and immune-mediated photodermatoses","volume":"149","author":"Guan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104344_b0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s13671-019-0263-z","article-title":"Chronic actinic dermatitis: a review","volume":"8","author":"Artz","year":"2019","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.drudis.2025.104344_b0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4103\/0378-6323.18946","article-title":"Chronic actinic dermatitis \u2013 a study of clinical features","volume":"71","author":"Somani","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.drudis.2025.104344_b0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1529-8019.2003.01607.x","article-title":"Diagnosis and treatment of chronic actinic dermatitis","volume":"16","author":"Dawe","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.drudis.2025.104344_b0145","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1440-0960.2003.00652.x","article-title":"Diagnosis and treatment of the common idiopathic photodermatoses","volume":"44","author":"Ferguson","year":"2003","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000092291","article-title":"Successful treatment of nodular actinic reticuloid with tacrolimus ointment","volume":"212","author":"Gr\u00f6ne","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.drudis.2025.104344_b0155","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/0190-9622(92)70261-D","article-title":"Successful treatment of musk ketone-induced chronic actinic dermatitis with cyclosporine and PUVA","volume":"27","author":"Gardeaz\u00e1bal","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0160","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaad.2008.08.020","article-title":"Solar urticaria","volume":"59","author":"Botto","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0165","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jaip.2015.04.006","article-title":"Solar urticaria","volume":"3","author":"Komarow","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.drudis.2025.104344_b0170","first-page":"542","article-title":"Erythropoietic protoporphyria and solar urticaria","volume":"179","author":"Farr","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0175","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archderm.139.9.1149","article-title":"Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases","volume":"139","author":"Beattie","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0180","series-title":"StatPearls","article-title":"Solar urticaria","author":"Harris","year":"2024"},{"key":"10.1016\/j.drudis.2025.104344_b0185","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.sder.2011.07.007","article-title":"Update on photodermatoses","volume":"30","author":"Santoro","year":"2011","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.drudis.2025.104344_b0190","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jaip.2018.03.007","article-title":"How to approach chronic inducible urticaria","volume":"6","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.drudis.2025.104344_b0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.2009.09451.x","article-title":"Photodermatoses: classification, evaluation and management","volume":"161","author":"Bylaite","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0200","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/phpp.12370","article-title":"Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature","volume":"34","author":"Morgado-Carrasco","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.drudis.2025.104344_b0205","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0190-9622(00)90127-0","article-title":"Hydroa vacciniforme: a clinical and follow-up study of 17 cases","volume":"42","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0210","series-title":"StatPearls","article-title":"Hydroa vacciniforme","author":"Rice","year":"2024"},{"key":"10.1016\/j.drudis.2025.104344_b0215","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archderm.142.5.587","article-title":"Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders","volume":"142","author":"Iwatsuki","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0220","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/1523-1747.ep12469648","article-title":"Pyridoxine toxicity to cultured fibroblasts caused by near-ultraviolet light","volume":"100","author":"Sato","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0225","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/BF00374081","article-title":"Photodynamic DNA-breaking activity of serum from patients with various photosensitivity dermatoses","volume":"287","author":"Hashizume","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.drudis.2025.104344_b0230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2133.1988.tb01757.x","article-title":"Hydroa vacciniforme: a review of ten cases","volume":"118","author":"Sonnex","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1525-1470.2011.01486.x","article-title":"Efficacy of \u03c9-3 polyunsaturated fatty acids for the treatment of refractory hydroa vacciniforme","volume":"29","author":"Durbec","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0240","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000246900","article-title":"Hydroa vacciniforme","volume":"189","author":"Ketterer","year":"1994","journal-title":"Dermatology"},{"key":"10.1016\/j.drudis.2025.104344_b0245","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104344_b0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Na Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104344_b0255","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: part I. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104344_b0265","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"key":"10.1016\/j.drudis.2025.104344_b0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.drudis.2025.104344_b0275","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.drudis.2025.104344_b0280","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104344_b0285","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"key":"10.1016\/j.drudis.2025.104344_b0290","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2025.104344_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110238","article-title":"JAK\/STAT signaling in rheumatoid arthritis leukocytes is uncoupled from serum cytokines in a subset of patients","volume":"264","author":"Dreo","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104344_b0300","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/jpm14070775","article-title":"Blocking the IL-4\/IL-13 axis versus the JAK\/STAT pathway in atopic dermatitis: how can we choose?","volume":"14","author":"Calabrese","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.drudis.2025.104344_b0305","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/ijms21041314","article-title":"The role of Th17-related cytokines in atopic dermatitis","volume":"21","author":"Sugaya","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104344_b0310","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1097\/MJT.0000000000001671","article-title":"Effectiveness of abrocitinib in a patient with chronic actinic dermatitis","volume":"31","author":"Jin","year":"2023","journal-title":"Am J Ther"},{"key":"10.1016\/j.drudis.2025.104344_b0315","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/exd.14493","article-title":"Pathogenesis of solar urticaria: classic perspectives and emerging concepts","volume":"31","author":"McSweeney","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0320","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104344_b0325","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1097\/DAD.0b013e3181c036de","article-title":"Atypical hydroa vacciniforme-like epstein-barr virus associated T\/NK-cell lymphoproliferative disorder","volume":"34","author":"Lee","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.drudis.2025.104344_b0330","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nbt.2019.04.002","article-title":"Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation","volume":"52","author":"Murer","year":"2019","journal-title":"New Biotechnol"},{"key":"10.1016\/j.drudis.2025.104344_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111846","article-title":"Deciphering JAK\/STAT signaling pathway: a multifaceted approach to tumorigenesis, progression and therapeutic interventions","volume":"131","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104344_b0340","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1756-8722-6-90","article-title":"STAT inhibitors for cancer therapy","volume":"6","author":"Furqan","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104344_b0345","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OARRR.S436637","article-title":"JAK-inhibitors \u2013 a story of success and adverse events","volume":"16","author":"Wlassits","year":"2024","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.drudis.2025.104344_b0350","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231178273","article-title":"Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis","volume":"14","author":"Mortezavi","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.drudis.2025.104344_b0355","article-title":"Safety and effectiveness of tofacitinib in treating polyarticular course juvenile idiopathic arthritis","volume":"15","author":"Jones","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.drudis.2025.104344_b0360","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40257-022-00684-1","article-title":"Baricitinib: a review in moderate to severe atopic dermatitis","volume":"23","author":"Hoy","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0365","article-title":"Current use of baricitinib in COVID-19 treatment and its future: an updated literature review","volume":"14","author":"Dupuis","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.drudis.2025.104344_b0370","first-page":"935","article-title":"Review of baricitinib in the treatment of alopecia areata","volume":"22","author":"Singh","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0375","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2025.104344_b0380","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/10600280221096713","article-title":"Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis","volume":"57","author":"Perche","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.drudis.2025.104344_b0385","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2025.104344_b0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.drudis.2025.104344_b0395","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2025.104344_b0400","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2016.09.008","article-title":"Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis","volume":"3","author":"Vesely","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.drudis.2025.104344_b0405","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15467","article-title":"Tofacitinib in resistant chronic actinic dermatitis: a case series","volume":"35","author":"Majid","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.drudis.2025.104344_b0410","doi-asserted-by":"crossref","first-page":"600","DOI":"10.25259\/IJDVL_744_2022","article-title":"Recalcitrant chronic actinic dermatitis responding to tofacitinib: a case report","volume":"89","author":"Dev","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.drudis.2025.104344_b0415","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/MJT.0000000000001616","article-title":"Improvement of refractory chronic actinic dermatitis during tofacitinib treatment","volume":"30","author":"Wang","year":"2023","journal-title":"Am J Ther"},{"key":"10.1016\/j.drudis.2025.104344_b0420","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/CCID.S451824","article-title":"Successful treatment of chronic actinic dermatitis with tofacitinib","volume":"17","author":"Zhong","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0425","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1002\/ski2.243","article-title":"Remission of chronic actinic dermatitis on baricitinib: a case report","volume":"3","author":"Maguire","year":"2023","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.drudis.2025.104344_b0430","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/ddg.15142","article-title":"Chronic actinic dermatitis with excellent response to oral baricitinib","volume":"21","author":"Agud-Dios","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.drudis.2025.104344_b0435","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ced\/llad348","article-title":"JAK-ing up chronic actinic dermatitis with upadacitinib","volume":"49","author":"Pappa","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0440","doi-asserted-by":"crossref","DOI":"10.1111\/ajd.14431","article-title":"Upadacitinib for chronic actinic dermatitis: a case report and literature review of JAK inhibitor use for recalcitrant disease","author":"Holmes","year":"2025","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0445","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1111\/ijd.17272","article-title":"Successful treatment of refractory late-onset actinic prurigo with tofacitinib","volume":"63","author":"Sardana","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0450","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/pde.15643","article-title":"Successful treatment of actinic prurigo with baricitinib in an 8-year-old child: a case report","volume":"41","author":"Malekan","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.drudis.2025.104344_b0455","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/ddg.15374","article-title":"Complete response of actinic prurigo to oral baricitinib","volume":"22","author":"Gil-Lianes","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.drudis.2025.104344_b0460","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1089\/derm.2023.0360","article-title":"Tofacitinib: a Treatment option for recalcitrant polymorphic light eruption and its mechanistic rationale","volume":"35","author":"Sardana","year":"2024","journal-title":"Dermatitis"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:16:18Z","timestamp":1758125778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1359644625000571"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104344","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors as a promising therapy for immune-mediated photodermatoses","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104344"}}